Journal Club 9/22/23

Monday, September 25, 2023

Last week, our researchers and physicians discussed a paper regarding the association of higher Ocrelizumab exposure with reduced disability progression in MS. Ocrelizumab, or Ocrevus, is a prescription drug commonly used to treat both progressive and relapsing-remitting MS. Ocrelizumab was shown to reduce new MRI lesion counts, and resulted in a lower annual relapse rate in RRMS patients. These findings suggest that higher exposure to Ocrelizumab may result in improved control of disability progression.

#tischms #curems #findacureforMS #tischMSRCNY

News Archive


Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy


Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.